Israeli firm Regentis BioMaterials files for $15M US IPO

Israeli company Regentis BioMaterials (RGBM) has filed for a potential $15 million initial public offering.

[{"selector":"#anim-0bc95df3-c159-4cac-833e-f9cbe26f3e2c","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-6d598b76-c8c3-4fe9-96eb-301cc921402b [data-leaf-element=\"true\"]","keyframes":{"transform":["translate(-9.746619507754275%, 0%) scale(1.5)","translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] The company aims to Nasdaq listing of its stock.

[{"selector":"#anim-71305322-6cc0-4376-8bdb-14286a4296ec","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-73051dbd-aacb-46a1-817f-21b222c58d37 [data-leaf-element=\"true\"]","keyframes":{"transform":["translate(-8.52941171736424%, 0%) scale(1.5)","translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] In November, the company submitted its initial IPO filing, with an accompanying filing fee schedule indicating.....

[{"selector":"#anim-d02dce2b-0240-482b-946c-eff34e9e733d","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-19e1a51e-9d62-4362-86b1-cbb563f4b051 [data-leaf-element=\"true\"]","keyframes":{"transform":["translate(0%, 0%) scale(1.5)","translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] By executing warrants, it hoped to generate up to $36 million.

[{"selector":"#anim-6b74330a-d5e6-4505-9401-a3e61cf86875","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-315ed46b-eabf-442f-855a-8fde47ff1aba [data-leaf-element=\"true\"]","keyframes":{"transform":["translate(0%, 0%) scale(1.5)","translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] Regentis, based in Or-Akiva, Israel, has created a degradable hydrogel known as GelrinC to cure excruciating knee cartilage injuries.

[{"selector":"#anim-ab8d50e5-051b-4180-b30e-f33040ce50db","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-e8bd4839-c649-456f-82c2-fd9edfaf6429 [data-leaf-element=\"true\"]","keyframes":{"transform":["translate(14.705882271317645%, 0%) scale(1.5)","translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] GenlrinC got market approval as a medical device in Europe in 2017, where the company plans to look for strategic partners.

[{"selector":"#anim-977263e4-85a9-47e8-a577-b0874e468cbc","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-be7a0b0b-3fe9-4ced-9784-254f4a9a0ca2 [data-leaf-element=\"true\"]","keyframes":{"transform":["translate(0%, 0%) scale(1.5)","translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] For the FDA's approval, Regentis is also conducting clinical trials.

[{"selector":"#anim-3919e7c8-42b4-46c1-92da-3a217435bf7d","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-5f3f68e0-5295-409e-a269-5c16bca62966 [data-leaf-element=\"true\"]","keyframes":{"transform":["translate(0%, 0%) scale(1.5)","translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] The medical device developer is currently operating in the red.

[{"selector":"#anim-9ed065b6-d2a6-43c3-8007-e5fb5ab4c6b8","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-14a6ff5b-0bf7-4169-87d5-673b9c889671 [data-leaf-element=\"true\"]","keyframes":{"transform":["translate(0%, 0%) scale(1.5)","translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] Regentis reported having no revenue and a net loss of $438K for the six-month period that ended on June 30.